Aberdeen Group plc Has $87.28 Million Position in Elevance Health, Inc. $ELV

Aberdeen Group plc raised its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 6.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 272,436 shares of the company’s stock after purchasing an additional 16,547 shares during the period. Aberdeen Group plc owned 0.12% of Elevance Health worth $87,276,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Cidel Asset Management Inc. grew its stake in Elevance Health by 18.2% in the 3rd quarter. Cidel Asset Management Inc. now owns 3,394 shares of the company’s stock valued at $1,097,000 after buying an additional 523 shares during the last quarter. IMA Advisory Services Inc. boosted its holdings in Elevance Health by 3.1% during the third quarter. IMA Advisory Services Inc. now owns 3,760 shares of the company’s stock valued at $1,215,000 after acquiring an additional 113 shares during the period. Assetmark Inc. grew its position in shares of Elevance Health by 28.2% in the third quarter. Assetmark Inc. now owns 86,775 shares of the company’s stock valued at $28,039,000 after purchasing an additional 19,078 shares during the last quarter. Public Sector Pension Investment Board increased its stake in shares of Elevance Health by 515.5% in the third quarter. Public Sector Pension Investment Board now owns 106,682 shares of the company’s stock worth $34,471,000 after purchasing an additional 89,350 shares during the period. Finally, Varma Mutual Pension Insurance Co increased its stake in shares of Elevance Health by 30.1% in the third quarter. Varma Mutual Pension Insurance Co now owns 45,782 shares of the company’s stock worth $14,793,000 after purchasing an additional 10,600 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wells Fargo & Company lowered their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Leerink Partners raised their price objective on shares of Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research note on Thursday, January 29th. Truist Financial dropped their target price on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Morgan Stanley reduced their price target on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a report on Wednesday, December 17th. Finally, TD Cowen restated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Trading Up 3.1%

Shares of ELV opened at $346.49 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a market cap of $76.47 billion, a PE ratio of 13.79, a PEG ratio of 1.93 and a beta of 0.50. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75. The stock has a 50 day simple moving average of $352.22 and a 200-day simple moving average of $332.30.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, sell-side analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $1.72 dividend. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.